Last reviewed 2026-04-23 · How we verify

Gynoclin V

Gynoclin V is a clindamycin-based vaginal formulation that inhibits bacterial protein synthesis to treat vaginal infections.

Gynoclin V is a clindamycin-based vaginal formulation that inhibits bacterial protein synthesis to treat vaginal infections. Used for Bacterial vaginosis, Vaginal infections caused by susceptible bacteria.

At a glance

Mechanism of action

Clindamycin is a lincosamide antibiotic that binds to bacterial ribosomes and inhibits protein synthesis, thereby reducing bacterial growth. Gynoclin V delivers clindamycin directly to the vaginal site of infection, allowing for local therapeutic concentrations while minimizing systemic exposure. This formulation is designed to treat bacterial vaginosis and other vaginal infections caused by susceptible anaerobic and aerobic bacteria.

Approved indications

• Bacterial vaginosis
• Vaginal infections caused by susceptible bacteria

Common side effects

• Vulvovaginal irritation
• Vaginal discharge
• Vulvovaginal candidiasis (secondary yeast infection)
• Abdominal pain

Key clinical trials

• A Study to Compare Efficacy and Safety of an Ovule Containing Terconazole, Clindamycin and Fluocinolone Versus an Ovule Containing Metronidazole, Nystatin and Fluocinolone in the Treatment of Secondary Vulvar/ or Vaginal Symptoms of Infectious Vaginitis/ and Infectious Vaginosis (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• Gynoclin V CI brief — competitive landscape report
• Gynoclin V updates RSS · CI watch RSS
• Janssen-Cilag, S.A. portfolio CI